Arrowhead stock surges on Phase 3 trial results

Arrowhead Pharmaceuticals reported positive topline results from two Phase 3 studies for its hypertriglyceridemia therapy.

The stock is on track to hit over 5-year highs following the breakthrough.

Arrowhead is targeting broader FDA approval based on the new data.